To what degree (P)RR blockade adds benefits on top of RAS blockade is still unknown. In the present study, we treated diabetic TGR(mREN2)27 rats, a well-established nephropathy model with high prorenin levels [allowing continuous (P)RR stimulation in vivo], with HRP on top of renin inhibition with aliskiren. Aliskiren alone lowered blood pressure and exerted renoprotective effects, as evidenced by reduced glomerulosclerosis, diuresis, proteinuria, albuminuria, and urinary aldosterone levels as well as diminished renal (P)RR and ANG II type 1 receptor expression. It also suppressed plasma and tissue RAS activity and suppressed cardiac atrial natriuretic peptide and brain natriuretic peptide expression. HRP, when given on top of aliskiren, did not alter the effects of renin inhibition on blood pressure, RAS activity, or aldosterone. However, it counteracted the beneficial effects of aliskiren in the kidney, induced hyperkalemia, and increased plasma plasminogen activatorinhibitor 1, renal cyclooxygenase-2, and cardiac collagen content. All these effects have been linked to (P)RR stimulation, suggesting that HRP might, in fact, act as a partial agonist. Therefore, the use of HRP on top of RAS blockade in diabetic nephropathy is not advisable.
tion in an ANG-independent manner, resulting in the activation of ERK1/2, cyclooxygenase (COX)-2, and fibrotic pathways (2, 37) . The latter includes enhanced transforming growth factor (TGF)-␤ 1 synthesis, plasminogen activator inhibitor (PAI)-1 release, and the upregulation of fibronectin and collagens (2, 18, 19, 37) . In agreement with this concept, ubiquitous expression of the human (P)RR in rats leads to proteinuria, glomerulosclerosis, and nephropathy, which could be reversed by the putative (P)RR blocker handle region peptide (HRP) (25) . Beneficial renal effects of HRP were also observed in ANG II type 1a receptor (AT 1a R)-deficient mice, suggesting that they are not solely due to interference with the RAS. However, the capacity of HRP to block (P)RR is controversial (34) , and recent studies (28, 38, 40) in knockout animals have suggested that (P)RR deletion in cardiomyocytes or podocytes is actually lethal. Thus, a relevant question is to what degree HRP should still be used, e.g., on top of RAS blockade in diabetic patients with nephropathy and heart failure. This is of particular importance now that the combination of two or more RAS blockers is no longer advocated in diabetic patients, since the side effect profile (hypotension and hyperkalemia) of this approach outweighs the beneficial effects (7, 39) .
In the present study, we therefore set out to study the effects of HRP on top of renin inhibition (with aliskiren) in a wellestablished high-prorenin model, the TGR(mRen2)27 (Ren2) rat, which overexpresses the mouse Ren2 gene (36) and also displays elevated (P)RR levels (5) . Aliskiren is renoprotective in this model, and its effects are comparable with those observed during AT 1 R blockade or ANG-converting enzyme inhibition, despite the nonequivalent blood pressure-lowering effects of these three types of RAS blockers (27, 45) . Cardioprotective effects of aliskiren have also been observed in diabetic rodents (10, 47) .
Rats were made diabetic with streptozotocin (STZ) and treated for 3 wk with aliskiren and/or HRP. We used a dose of HRP that has been applied before in several rodent studies (12, 22, 23, 25) . We reasoned that, if anywhere, the beneficial effects of this putative (P)RR blocker on the kidney and heart should be observed in this high-prorenin, high-(P)RR model.
METHODS

Animal Experiments
Homozygous Ren2 rats (400 -500 g, a kind gift from Dr. M. Bader, Berlin, Germany) were crossed with Sprague-Dawley rats (Harlan, Boxmeer, The Netherlands) to generate heterozygous Ren2 rats. Heterozygous rats were subsequently used in all experiments, since these rats, in contrast to homozygous Ren2 rats, did not require lisinopril treatment (10 g/ml in drinking water) to decrease mortality. All experiments were performed under the regulation and permission of the Animal Care Committee of the Erasmus MC. Rats were housed in individual cages and maintained on a 12:12-h light-dark cycle with access to standard laboratory rat chow and water ad libitum. Radiotelemetry transmitters were implanted as previously described (42) for continuous measurements of heart rate, blood pressure, and activity. Two weeks later, to induce diabetes mellitus (DM), rats were fasted overnight and administered STZ (1 injection of 55 mg/kg STZ ip, Sigma-Aldrich, Zwijndrecht, The Netherlands). Rats were checked for nonfasting blood glucose and ␤-ketone levels by tail incision daily during the first 3 days after STZ injection and once weekly thereafter (Precision Xceed, Abbott, Zwolle, The Netherlands). Only rats with glucose levels of Ͼ15 mM were considered diabetic, and they subsequently received 2-4 U insulin/day (Levemir, Novo Nordisk, Denmark). Diabetic Ren2 rats had an average blood glucose level of 25.8 Ϯ 0.9 mmol/l. After 2 wk of DM status, osmotic minipumps (2ML4, Alzet) were implanted subcutaneously under isoflurane anesthesia to infuse vehicle (saline, n ϭ 8), aliskiren (a gift from Novartis, 10 mg·kg Ϫ1 ·day Ϫ1 , n ϭ 8), or aliskiren ϩ rat HRP (NH2-RILLKKMPSV-COOH, 1 mg·kg Ϫ1 ·day Ϫ1 , Biosynthan, Berlin, Germany, n ϭ 7). In animals that received aliskiren ϩ HRP, two separate minipumps were implanted in both sides of the body. During the study, rats were placed in metabolic cages on day Ϫ14 (non-DM), day 0 (DM), and day 21 (DM ϩ treatment) to collect 24-h urine. Each rat served as its own control for the non-DM state. Urine was frozen and stored until analysis of total protein, albumin, creatinine, Na ϩ , endothelin (ET)-1, and aldosterone. After three weeks of treatment, animals were anesthetized by an intraperitoneal pentobarbital injection, and the hepatic portal vein was cannulated to collect blood for measurements of ANG I, ANG II, aldosterone, ET-1, TGF-␤ 1, PAI-1, K ϩ , cystatin C (a marker of glomerular filtration that is less dependent on muscle mass compared with creatinine), and creatinine (day 21). The kidney and heart were excised, weighed, divided into transverse segments, and fixed in 4% paraformaldhyde for histological analysis or frozen in liquid nitrogen for gene expression analysis. Blood and organs were also obtained from six DM Ren2 rats treated with saline for 3 wk and eight untreated non-DM Ren2 rats, which did not undergo hemodynamic measurements. 
HPRT-1, hypoxanthine phosphoribosyltransferase 1; TGF-␤1, transforming growth factor-␤1; (P)RR, (pro)renin receptor; AT1R, angiotensin II type 1 receptor; COX-2, cyclooxygenase 2; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; ␤-MHC, ␤-myosin heavy chain; Ngal, neutrophil gelatinase-associated lipocalin. Data are means Ϯ SE; n ϭ 7-8 rats/group. Non-DM, nondiabetic; DM, diabetic; HRP, handle region peptide; ND, not determined. Creatinine clearance in non-DM rats could not be calculated since plasma and urine creatinine levels in this group were determined on day 21 and day Ϫ14, respectively, i.e., not on the same day. *P Ͻ 0.05 vs. non-DM rats; †P Ͻ 0.05 vs. vehicle. ‡Data are from Batenburg et al. (3) .
Biochemical Measurements
ET-1 was assessed by chemiluminescent ELISA (QuantiGlo, R&D Systems), albumin by enzyme immunoassay (Spi-Bio, Montigny-LeBretonneux, France), and aldosterone by radioimmunoassay (Coata-Count, Siemens Medical Solutions Diagnostics, Los Angeles, CA). TGF-␤ 1, cystatin C (Quantikine, R&D systems), and PAI-1 (Zymutest, Tebu-Bio, Le Perray-en-Yvelines, France) were measured by ELISA. Creatinine, K ϩ , Na ϩ , and total protein were measured at the clinical chemical laboratory of the Erasmus MC. ANG I and ANG II were measured by radioimmunoassay, after SepPak extraction and reverse-phase HPLC separation as previously described (6, 8) .
Histology
After fixation, kidney and heart sections were dehydrated and paraffin embedded. Gomori silver staining was applied to sections (5 m) of the left ventricle of the heart to visualize individual cardiomyocytes. Sirius red staining was applied to visualize collagen as a measure of cardiac fibrosis. Cardiomyocyte size and the amount of collagen were measured using Qwin (Leica).
Transversely sliced kidney sections (deparaffinized, 2 m) were stained with periodic acid-Schiff to localize kidney damage and ␣-smooth muscle actin to identify interlobar arteries. The glomerular volume, arterial wall thickness, and lumen diameter of interlobar arteries were blindly assessed in the sections. To measure glomerular volume, 50 individual glomeruli from each kidney section were traced along Bowman's capsule to measure glomerular circumference using the system of NanoZoomer Digital Pathology. Glomerular volume was calculated from the glomerular circumference and radius according the method of van Damme et al. (41) using the following formula: 4/3r 2 , where r is the radius. To measure the arterial wall thicknessto-lumen diameter ratio, the arterial and lumen circumference of 6 interlobar arteries/kidney section was measured using the system of NanoZoomer Digital Pathology. Arterial wall thickness was calculated by deduction of the lumen radius from the arterial outer radius. Data were also expressed as arterial wall thickness divided by the lumen diameter ratio to correct for the size of the arteries measured.
The presence of focal segmental glomerulosclerosis was assessed in all glomeruli of one kidney section per animal with a mean of 181 Ϯ 4 glomeruli per section. All sections were semiquantitatively scored by a renal pathologist in a blinded manner. Renal scarring of all glomeruli was scored on an arbitrary scale from 0 to 4, where grade 0 (n0) indicates no glomerulosclerosis, grade 1 (n1) indicates Ͻ25% of sclerosis, grade 2 (n 2) indicates 25-50% of sclerosis, grade 3 (n3) indicates 50 -75% of sclerosis, and grade 4 (n4) indicates Ͼ75% of sclerosis per glomerulus. Hereafter, the individual glomerulosclerosis index (GSI) was calculated for each rat with the following formula: [(1ϫn 1) 
Furthermore, 10 images of each kidney section (ϫ100 magnification) were analyzed for arterial hyalinosis, intima fibrosis, and mediahypertrophy as well as tubular atrophy, interstitial fibrosis, and renal inflammation according to the Banff classification (35) . Each parameter was graded in 10 fields with a score of 0 -3, in which 0 indicates no changes in pathology, grade 1 indicates Ͻ25% of change, grade 2 indicates 25-50% of change, and grade 3 indicates Ͼ50% of change in affected tissue. From these data, the tubulointerstitial score was calculated by dividing the combined score of tubular atrophy, interstitial fibrosis, and renal inflammation with the number of parameters.
Quantitative Real-Time RT-PCR
Total RNA was isolated from snap-frozen rat kidneys and hearts using TRIzol (Life Technologies) and reverse transcribed into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen, Venlo, The Netherlands). The resulting cDNA was amplified for 40 cycles (denaturation at 95°C for 10 min, thermal cycling at 95°C for 15 s, and annealing/extension at 60°C for 1 min) with a Step-One cycler (NYSE, Life Technologies) using SYBR Green PCR Master Mix (Life Technologies). The intron-spanning oligonucleotide primers for quantitative PCR were designed with Primer-BLAST (National Center for Biotechnology Information; Table 1 ). The comparative cycle time method (⌬⌬CT, where CT is threshold cycle) was used for the relative quantification of gene expression using the geometric mean of the housekeeping genes hypoxanthine phosphoribosyl transferase-1, urinary Na ␤2-microglobulin, and ␤-actin for normalization. In cardiac left ventricular tissue, gene expression of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), ␤-myosin heavy chain (␤-MHC), (P)RR, and AT1R was determined. Gene expression of rat renin, (P)RR, AT1R, collagen-1, TGF-␤1, TNF-␣, NF-B, COX-2, and neutrophil gelatinase-associated lipocalin (Ngal; a marker of tubular damage) was measured in the kidney medulla and cortex.
Statistical Analysis
Statistical analysis was performed using an unpaired t-test after one-way ANOVA with a Bonferroni posttest confirmed differences between groups. Data are given as means Ϯ SE. P values of Ͻ0.05 were considered significant.
RESULTS
Animal Characteristics
Hemodynamic data have been previously reported (3). In brief, diabetic Ren2 rats were severely hypertensive, and a 3-wk treatment with aliskiren (but not vehicle) lowered blood pressure ( Table 2 ). The effect on blood pressure was unaltered by HRP. Diabetic Ren2 rats displayed reduced body weight and heart weight and an increased kidney weight; as a result, the heart weight-to-body weight ratio was unaltered in diabetic animals, whereas their kidney weight-to-body weight ratio was increased (Table 2) . Treatment with aliskiren with or without HRP did not affect these parameters.
Biochemical Measurements
STZ-induced DM increased blood glucose in Ren2 rats approximately fourfold, and this was unaffected by treatment (Table 2) . DM increased urinary volume time dependently. It was up Ϸ4-fold after 2 wk and after an additional 3 wk (during treatment with vehicle) Ϸ13-fold (Fig. 1) . Aliskiren prevented this rise in diuresis, most likely due to its effects on blood pressure, whereas HRP negated the protective effects of aliskiren. Changes in urinary protein and albumin ran in parallel with the changes in urinary volume, although HRP did not prevent the effect of aliskiren on albumin (Fig. 1) .
DM decreased plasma creatinine, and this was unaffected by aliskiren treatment. HRP, when given on top of aliskiren, normalized plasma creatinine. No significant changes in urinary creatinine or creatinine clearance were observed after DM induction with or without treatment (Table 2 ). Likewise, there was no change in plasma cystatin C, indicating no change in the glomerular filtration rate due to 5 wk of DM with or without treatment (Fig. 3) .
DM marginally decreased plasma renin activity [P ϭ not significant (NS)], and this was accompanied by a significant decrease in ANG levels in the heart and kidney (Fig. 2) . Aliskiren further reduced these levels in the kidney, both with and without HRP. Plasma aldosterone levels were also decreased in diabetic Ren2 rats, and this resulted in increased natriuresis and a (nonsignificant) increase in plasma K ϩ levels (Fig. 3) . Remarkably, despite the reduction in plasma aldosterone, urinary aldosterone excretion rose eightfold. Aliskiren ( Table 2 ). Plasma and urinary ET-1 levels were unaffected by DM or treatment ( Table 2) .
The Kidney
Gene expression. DM did not alter rat renin, AT 1 R, COX-2, or Ngal expression in the medulla or cortex (Fig. 4) . It increased (P)RR and collagen-1 expression in the medulla and, to a lesser degree (P ϭ NS), in the cortex. DM decreased TGF-␤ 1 expression in the cortex, whereas it induced a nonsignificant increase in TGF-␤ 1 expression in the medulla. Similar changes were observed for TNF-␣ and NF-B, but these were not significant (data not shown). Aliskiren did not alter DMinduced changes in TGF-␤ 1 and collagen-1 and increased cortical rat renin expression. A similar increase in renin expression, albeit nonsignificant, was observed in the medulla. Aliskiren diminished cortical (P)RR and AT 1 R expression without affecting these parameters in the medulla. Aliskiren tended to increase cortical COX-2 expression (P ϭ NS). Changes by aliskiren were unaltered in the presence of HRP except for the increase in COX-2, which became significant after the addition of HRP.
Histology. DM did not alter tubulointerstitial score, glomerular volume, interlobar arterial lumen diameter, and wall thickness (nor the ratio of the latter two) and nonsignificantly decreased GSI (Fig. 5) . Arterial hyalinose, intima fibrosis, and media hypertrophy were not observed. Aliskiren reduced GSI without affecting any of the other parameters. HRP, when given on top of aliskiren, did not alter its effects on GSI but tended to increase glomerular volume and lumen diameter, with the latter resulting in a decrease in the lumen diameterto-wall thickness ratio. However, none of these changes were significant.
The Heart
Gene expression. DM did not affect cardiac ANP, BNP, and (P)RR expression and increased ␤-MHC and AT 1 R expression (Fig. 6) . Aliskiren with HRP, but not aliskiren alone, normalized the latter. Drug treatment did not affect (P)RR or ␤-MHC expression. Aliskiren, with or without HRP, reduced cardiac BNP expression, and similar trends were observed for cardiac ANP expression, although the changes were significant only during combination treatment.
Histology. DM increased cardiac collagen content without altering myocyte size. Aliskiren did not affect these changes, whereas aliskiren with HRP further increased collagen content and marginally diminished myocyte size (Fig. 7) .
DISCUSSION
This study shows that HRP counteracts the favorable effects of aliskiren on early renal damage in diabetic Ren2 rats. In agreement with previous studies (3, 26) , the hypertensive Ren2 rat, when made diabetic with STZ, displayed mild glomerulosclerosis, accompanied by albuminuria, proteinuria, and diuresis. A 3-wk treatment with aliskiren improved these parameters, whereas the addition of HRP on top of aliskiren negated the protective effects of aliskiren on the latter two. HRP also induced hyperkalemia and increased plasma PAI-1, renal COX-2, and cardiac collagen content. This argues against the application of HRP in combination with aliskiren in diabetic patients.
Plasma creatinine decreased after the induction of DM, most likely reflecting the weight (and muscle) loss occurring in these animals. There were no changes in cystatin C or renal Ngal expression, suggesting that indeed the renal damage in our DM animals was at an early stage, not yet resulting in alterations in glomerular filtration or tubular damage. Of interest, aliskiren alone did not alter these parameters, whereas HRP on top of aliskiren increased plasma creatinine and tended to increase (P ϭ NS) cortical Ngal expression, again suggesting that HRP, if anything, worsened renal function when combined with aliskiren.
DM reduced plasma, cardiac, and renal RAS activity in the Ren2 rat, although only the reduction in tissue was significant. The reduction in plasma renin activity was modest, in full agreement with the consequence of diabetes in humans (15) . Along with this RAS suppression, plasma aldosterone decreased by almost 50%. Not surprisingly, this resulted in natriuresis and a (nonsignificant) rise in plasma K ϩ . Yet, urinary aldosterone excretion increased eightfold. This is suggestive for a net rise in adrenal aldosterone production, most likely to compensate the loss of aldosterone via urine (Ϸ1.5 ng/day). Of interest, aliskiren greatly diminished the urinary aldosterone loss, reflecting a reduction in aldosterone production, although plasma aldosterone, if anything, tended to go up, thereby counteracting the above effects on natriuresis and hyperkalemia. The effects of aliskiren on aldosterone and natriuresis were unaltered by HRP. However, it greatly elevated plasma K ϩ . Since this occurred independently of changes in aldosterone, it might be the consequence of direct effects of HRP, e.g., via (P)RR (31) .
The aliskiren-induced reduction in renal ANG content, together with the reduction of cortical AT 1 R expression, probably underlies the beneficial effect of renin inhibition in the kidney. Aliskiren-induced AT 1 R suppression has been previously reported, both in the kidney and other organs (11, 30, 43) . At 5 wk after STZ injection, we observed modest regional changes in renal TGF-␤ 1 , TNF-␣, NF-B, and collagen-1 expression, although no fibrosis or inflammation could be detected. It is therefore not surprising that aliskiren did not significantly affect these parameters in the kidney. Such effects have been observed before, but this required a longer duration of DM (10 wk) and aliskiren treatment starting at the moment of STZ injection (11) . HRP did not alter the effect of aliskiren on TGF-␤ 1 but unexpectedly increased the levels of PAI-1. These observations contrast with the idea that HRP prevents (pro)renin-(P)RR interactions, thereby blocking the rise in PAI-1 that result from such (P)RR stimulation, at least in vitro (19, 48) . Possibly, the increase in renal (rat) renin expression after aliskiren was too modest to increase PAI-1. In addition, aliskiren suppressed (P)RR expression. Recently, HRP has been reported to act as a partial agonist of (P)RR (31, 46) . Thus, its stimulatory effects on PAI-1 on top of aliskiren might also be the consequence of direct (P)RR stimulation.
Hyperglycemia elevates (P)RR expression in rat mesangial cells via PKC, ERK1/2, and JNK (17) , and this has been suggested to facilitate ANG II generation and AT 1 R-dependent COX-2 induction (13). Ubiquitous overexpression of human (P)RR in the rat also resulted in COX-2 upregulation (25). Simultaneously, COX-2 inhibition reduced the glucose-induced (P)RR upregulation, suggesting that COX-2 itself upregulates (P)RR (16) . Our study confirms renal (P)RR upregulation in diabetic Ren2 rats. However, significant COX-2 upregulation was only seen after concomitant HRP administration, even in the face of aliskiren-induced (P)RR suppression. This suggest that (P)RR upregulation per se is insufficient to increase COX-2 and requires additional (P)RR stimulation, either by renin, HRP, or their combination. COX-2 elevation has been previously reported in the macula densa after renin upregulation due to salt restriction (14) . Such COX-2 upregulation has detrimental effects, for instance, COX-2 generated endothelium-derived contractile factors in diabetic Ren2 rats, thereby inducing vascular dysfunction (3), and the COX-2 upregulation in human (P)RR-overexpressing rats was accompanied by proteinuria and glomerulosclerosis (25) . Natriuretic peptides are released by the hypertrophied heart, and their levels are elevated in patients with heart failure (4) and in homozygous Ren2 rats (44) . Aliskiren reduced cardiac ANP and BNP expression in the diabetic, heterozygous Ren2 rats of the present study, most likely due to its blood pressurelowering effect. Yet, aliskiren did not affect cardiac hypertrophy, ␤-MHC expression, or myocyte size. These effects were unaltered by HRP. Moreover, no changes occurred in cardiac (P)RR expression, suggesting that (P)RR upregulation by hyperglycemia is not a uniform phenomenon. Although aliskiren with or without HRP did not significantly reduce cardiac ANG content, HRP combined with aliskiren did suppress cardiac AT 1 R expression, suggesting that this combination may have reduced the consequences of ANG II-AT 1 R interactions. However, this did not result in a reduction of cardiac fibrosis, possibly because the degree of fibrosis in our model was still modest. Remarkably, however, cardiac fibrosis increased significantly after cotreatment of aliskiren with HRP. This contrasts with a previous study (21) showing antifibrotic effects of HRP in stroke-prone spontaneously hypertensive rats and once again illustrates the partial agonistic capacities of HRP.
In conclusion, renin inhibition improves renal function in diabetic Ren2 rats with early kidney damage, and (P)RR blockade with HRP not only counteracted this effect in a RAS-independent manner but also increased K ϩ , PAI-1, renal COX-2, and cardiac fibrosis. This contrasts with the beneficial cardiac and renal effects of HRP observed in various models (20, 22, 24) but agrees with the deleterious effects of (P)RR knockout in the heart and kidney (28, 40) . A uniform explanation might be that HRP acts as a partial agonist (43, 46) . Nevertheless, given these controversial findings, it seems that, at this stage, HRP should not be considered as add-on drug in diabetics treated with a RAS inhibitor. Furthermore, given the uncertainty whether HRP is a (P)RR blocker or not, future studies should carefully examine the exact function of (P)RR in diabetes, e.g., making use of (inducible) renal cell-specific knockout models, to define its role as a treatment target.
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